Payment overview · 2025
General Payments
$5,969.12
271 reported records · 35 companies
Healthcare provider profile · identity verified
John Michael Demicco, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAVANNAH, GA · NPI 1285632125
Verified facts
What the public records show
CMS Open Payments records show John Michael Demicco, M.D. received $5,969.12 in general payments during 2025 across 271 reported records.
ABBVIE INC. accounted for 12.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 50 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Farxiga, Jardiance, Kerendia, Kevzara, Krystexxa, Linzess, Mounjaro, Ozempic, Rinvoq, Rybelsus, Sunosi, Trelegy Ellipta, Tremfya, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KRYSTEXXA as an associated drug or biological on 45998 records involving 14548 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Krystexxa by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Auvelity by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Sunosi by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kevzara by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Actemra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Benlysta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tremfya by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 1375 records involving 893 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Tremfya by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $757.63 | 12.7% | 33 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $677.95 | 11.4% | 38 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $520.68 | 8.7% | 26 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $472.37 | 7.9% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $419.96 | 7.0% | 13 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $395.92 | 6.6% | 15 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $298.13 | 5.0% | 16 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $291.07 | 4.9% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $265.62 | 4.5% | 10 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $259.44 | 4.3% | 10 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $235.23 | 3.9% | 9 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $186.76 | 3.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.02 | 3.0% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $137.02 | 2.3% | 8 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $115.07 | 1.9% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $84.86 | 1.4% | 3 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $75.81 | 1.3% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.71 | 1.1% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $54.11 | 0.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.73 | 0.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.46 | 0.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $42.01 | 0.7% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.22 | 0.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $31.97 | 0.5% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $29.67 | 0.5% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $28.32 | 0.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.02 | 0.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $27.32 | 0.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.14 | 0.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.95 | 0.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.97 | 0.4% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $25.14 | 0.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.82 | 0.4% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $18.41 | 0.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.61 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,712.09 | 266 |
| Education | $257.03 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $520.68 | 26 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $485.36 | 17 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $472.37 | 24 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $459.46 | 19 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $395.92 | 15 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $298.13 | 16 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $291.07 | 12 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $281.52 | 9 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $235.23 | 9 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $229.75 | 9 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $215.58 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $172.81 | 17 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $149.05 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.79 | 10 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $122.38 | 7 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $115.07 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $108.36 | 9 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $98.77 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $84.86 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $79.07 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $75.81 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.97 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.71 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.40 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $54.11 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.04 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $45.68 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Biological, Drug | Octapharma USA, Inc., PFIZER INC. | $44.31 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.22 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $31.97 | 1 | 2025 |
Source payment records
|
|||||
| JUBBONTI Normalized: jubbonti |
Biological | Sandoz Inc. | $29.69 | 1 | 2025 |
Source payment records
|
|||||
| Gazyva Normalized: gazyva |
Biological | Genentech USA, Inc. | $28.32 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| RENFLEXIS Normalized: renflexis |
Drug | Organon LLC | $27.32 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $27.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.97 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.30 | 2 | 2025 |
Source payment records
|
|||||
| Tyenne Normalized: tyenne |
Biological | Fresenius Kabi USA, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $5.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 133 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KRYSTEXXA krystexxa |
2025 | Krystexxa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 192 | exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 258 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
| Sunosi sunosi |
2025 | Sunosi | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 53 | exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
258 | 45 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | KRYSTEXXA open payments reported associated product |
CMS Open Payments — General Payments 45998 supporting records · 14548 recipient NPIs · example record 1226871690 |
Krystexxa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
133 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Sunosi open payments reported associated product |
CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059 |
Sunosi · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 1375 supporting records · 893 recipient NPIs · example record 1174223585 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
192 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 768 | 209 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 625 | 95 |
| Methotrexate | Methotrexate Sodium | 475 | 132 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 435 | 80 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 374 | 113 |
| Duloxetine Hcl | Duloxetine Hcl | 325 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 318 | 93 |
| Pregabalin | Pregabalin | 300 | 70 |
| Atorvastatin Calcium | Atorvastatin Calcium | 290 | 85 |
| Trazodone Hcl | Trazodone Hcl | 288 | 74 |
| Omeprazole | Omeprazole | 280 | 70 |
| Gabapentin | Gabapentin | 265 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 68 |
| Rinvoq | Upadacitinib | 258 | 45 |
| Lisinopril | Lisinopril | 234 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 209 | 60 |
| Tramadol Hcl | Tramadol Hcl | 201 | 53 |
| Ozempic | Semaglutide | 192 | 35 |
| Enbrel Sureclick | Etanercept | 189 | 26 |
| Furosemide | Furosemide | 188 | 66 |
| Metformin Hcl | Metformin Hcl | 185 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 49 |
| Alprazolam | Alprazolam | 173 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 163 | 19 |
| Celecoxib | Celecoxib | 159 | 58 |
| Famotidine | Famotidine | 156 | 40 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 152 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 151 | 49 |
| Losartan Potassium | Losartan Potassium | 145 | 45 |
| Farxiga | Dapagliflozin Propanediol | 133 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 38 |
| Meloxicam | Meloxicam | 122 | 45 |
| Allopurinol | Allopurinol | 121 | 39 |
| Ibuprofen | Ibuprofen | 117 | 43 |
| Lorazepam | Lorazepam | 115 | 25 |
| Sertraline Hcl | Sertraline Hcl | 114 | 24 |
| Promethazine Hcl | Promethazine Hcl | 112 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 112 | 30 |
| Valsartan | Valsartan | 109 | 32 |
| Carvedilol | Carvedilol | 102 | 29 |
| Clonidine Hcl | Clonidine Hcl | 101 | 31 |
| Atenolol | Atenolol | 97 | 26 |
| Clonazepam | Clonazepam | 97 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 30 |
| Donepezil Hcl | Donepezil Hcl | 96 | 34 |
| Buspirone Hcl | Buspirone Hcl | 95 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 34 |
| Simvastatin | Simvastatin | 94 | 26 |
| Humira(Cf) Pen | Adalimumab | 90 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 87 | 26 |
| Potassium Chloride | Potassium Chloride | 83 | 22 |
| Fluconazole | Fluconazole | 82 | 31 |
| Glipizide Er | Glipizide | 75 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 23 |
| Pilocarpine Hcl | Pilocarpine Hcl | 72 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 17 |
| Colchicine | Colchicine | 71 | 32 |
| Xeljanz Xr | Tofacitinib Citrate | 71 | suppressed |
| Amoxicillin | Amoxicillin | 70 | 45 |
| Mounjaro | Tirzepatide | 69 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 21 |
| Rybelsus | Semaglutide | 66 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 66 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 20 |
| Glipizide | Glipizide | 63 | 18 |
| Nifedipine Er | Nifedipine | 62 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 60 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 58 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 22 |
| Linzess | Linaclotide | 56 | 16 |
| Vascepa | Icosapent Ethyl | 56 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 29 |
| Alendronate Sodium | Alendronate Sodium | 55 | 23 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Spironolactone | Spironolactone | 54 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 53 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 14 |
| Diazepam | Diazepam | 51 | 13 |
| Eliquis | Apixaban | 50 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 48 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 11 |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 43 | 15 |
| Metformin Hcl Er | Metformin Hcl | 42 | 16 |
| Modafinil | Modafinil | 41 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 28 |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Benlysta | Belimumab | 39 | suppressed |
| Adalimumab-Adaz(Cf) Pen | Adalimumab-Adaz | 38 | 11 |
| Montelukast Sodium | Montelukast Sodium | 38 | 14 |
| Dexlansoprazole Dr | Dexlansoprazole | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Folic Acid | Folic Acid | 36 | 16 |
| Nystatin | Nystatin | 36 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 14 |
| Metolazone | Metolazone | 35 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 23 |
| Ondansetron Odt | Ondansetron | 35 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 12 |
| Carisoprodol | Carisoprodol | 34 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Bumetanide | Bumetanide | 29 | suppressed |
| Lansoprazole | Lansoprazole | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Prolia | Denosumab | 28 | 18 |
| Hyrimoz(Cf) Pen | Adalimumab-Adaz | 27 | 11 |
| Sunosi | Solriamfetol Hcl | 27 | suppressed |
| Calcipotriene | Calcipotriene | 26 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 26 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | 11 |
| Scopolamine | Scopolamine | 26 | 17 |
| Vraylar | Cariprazine Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Tremfya | Guselkumab | 24 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Enbrel Mini | Etanercept | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Savella | Milnacipran Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 17 |
| Cimzia (2 Pack) | Certolizumab Pegol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Cortrophin | Corticotropin | 18 | suppressed |
| Krystexxa | Pegloticase | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Enbrel | Etanercept | 17 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Mupirocin | Mupirocin | 16 | 14 |
| Temazepam | Temazepam | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Actemra | Tocilizumab | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Osphena | Ospemifene | 13 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hadlima(Cf) Pushtouch | Adalimumab-Bwwd | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tretinoin | Tretinoin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Humira Pen | Adalimumab | 11 | suppressed |
| Hydroxyurea | Hydroxyurea | 11 | suppressed |
| Kevzara | Sarilumab | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,969.12 · 271 records | ABBVIE INC. | ACTHAR, AIRSUPRA, BENLYSTA, Bimzelx, CAPLYTA, COSENTYX, Cologuard Collection Kit, EVENITY, FARXIGA, GIVLAARI, Gazyva, General - Pain Management, HADLIMA, HYRIMOZ, IBSRELA, JARDIANCE, JUBBONTI, KEVZARA, KRYSTEXXA, Kerendia, LINZESS, LUPKYNIS, MOUNJARO, OCTAGAM IMMUNE GLOBULIN (HUMAN), OPSUMIT, ORENCIA, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, RENFLEXIS, REXULTI, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, SPRAVATO, Sunosi, TRELEGY ELLIPTA, TREMFYA, Tyenne, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WAKIX, Wegovy, XELJANZ, XIFAXAN, ZEPBOUND | 30 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error